This round is no longer accepting investments, but hundreds just like it are live now.

Log In


Automated Lymphatic Therapy (ALT) Technology

Eva Medtec is a medical technology enterprise that launched commercially in 2021 with its flagship product, the Neuroglide™, and has raised $3.7M to date.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$104,832.79 Raised


The Neuroglide™ by Eva Medtec makes it possible for anyone to experience the benefits of automated lymphatic therapy with one simple, at-home system. The company’s proprietary technology has received FDA-clearance for pain relief and increased circulation, which has numerous physical health benefits.

By developing non-invasive solutions that can be accessed without the need for a prescription, Eva Medtec is targeting the $4B Pain Management Devices market, which is expected to reach more than $8.5B by 2030 (8.5% CAGR). With additional therapy attachments currently in development, Eva Medtec also plans to address the $18.6B Stress Management Market as well as the $30B+ Sleep Health Market as the company looks to expand the Neuroglide’s FDA labeling.*

At the helm of Eva Medtec’s operations is a team of passionate founders with decades of combined medical and marketing experience seeking to continually evolve the company’s product pipeline with new innovations for the med-tech market. All products developed by Eva Medtec are based on extensive in-field expertise and are made in the U.S. by a full, in-house manufacturer.

*Market information provided by Precedence Research, Globe Newswire, and McKinsey & Company (source, source, source)

the pitch

Eva Medtec is the creator and manufacturer of Neuroglide™, an over-the-counter, FDA-cleared medical device engineered to automate and emulate manual lymphatic drainage (MLD) therapy. Lymphatic fluid carries toxins and other debri from cells of the body. When this fluid builds up in the lymphatic vessels, the body can have a number of negative reactions, including swelling and discomfort. MLD therapy seeks to accelerate lymph flow and decongest the body’s soft tissues of excess lymph, a practice with many associated health benefits – including pain management, improved rest, relaxation, and recovery. 

Holistic Methodology Meets Modern Innovation

The Neuroglide™ is a back and neck device that emulates the precise pressure profiles and principles of manual lymphatic drainage (MLD) therapy in order to make this highly-specialized modality more available and accessible to all.

The technology was developed with the expertise of a certified MLD therapist, Eva Medtec's Founder & CTO, Irene Waldridge. Irene previously founded a publicly traded, market-leading lymphedema company, Tactile Medical (NASDAQ: TCMD), which at one point held a $1.2B market cap.* Irene’s experience practicing the techniques of MLD led her to witness its many health benefits firsthand. Because lymphatic therapy supports the body’s immune and autonomic nervous systems, MLD treatment has the potential to improve patient outcomes in cases of acute pain, injury, chronic pain, and other chronic conditions.

*Eva Medtec's leadership experience is not a guarantee of future performance or success.

The Problem & Our Solution

Bringing Together Technique and Technology to Provide Therapeutic At-Home Care

In recent years, more medical and therapeutic professionals have begun to recognize the body’s lymphatic system as having an important impact on overall health and wellness. Increased lymph circulation is linked to improved immune function, as well as reduction of swelling, congestion, and inflammation. However, because MLD therapy is an advanced modality available only through a handful of certified professional practitioners, most people aren’t able to access lymphatic therapy as often as needed for it to be truly effective.


Understanding this, Eva Medtec sought to develop a fully-automated device that can be used from the comfort of home, capable of producing benefits similar to receiving hands-on treatment. Utilizing an array of air channels that inflate and deflate in sequence, the Neuroglide™ is able to emulate the proper pressure, tempo, and mechanics needed to access the lymphatic system, promoting healthy flow of lymph throughout the entire body. This technology has been cleared by the FDA for pain relief and increased circulation, and is easy to use, anywhere, at any time.

The Market & Our Traction

Backed by Science and Built to Serve Multiple Market Verticals

In order to introduce the Neuroglide™ to the commercial market, Eva Medtec has obtained Class II FDA clearance for pain relief and increased circulation, as well as utility patent status for our proprietary technology. With these proof-positive elements in place, the company has been able to generate our first $100K in sales.

In pilot clinical patient trials, users of Neuroglide™ reported reduced back and neck pain, more restorative and consistent sleep, improved athletic recovery, and reduced pain from fibromyalgia. 

As Eva Medtec works to expand awareness and accessibility to MLD therapy, the company is equally as excited about the planned, future therapy devices currently in development. These devices are designed for use with specific body regions such as the knee, lower legs, lumbar, and head, and work with the Neuroglide’s Controller Unit at launch. In addition to further developing the company’s product line, Eva Medtec also plans to expand Neuroglide’s FDA labeling into other benefit cases such as improved sleep, stress reduction, and athletic recovery.

Why Invest

Trusted Technology on Trend to Provide Positive Impact

As lymphatic therapies and MLD continue to generate a buzz in the medical sector as well as amongst A-list celebrities, such as Jennifer Aniston, the Kardashians, and Ariana Grande, Eva Medtec anticipates a growing trend of consumers looking to experience its many health benefits for themselves. Even so, because MLD remains a niche modality available only to a limited market, the company expects automated devices such as the Neuroglide™ have great potential to be widely embraced by at-home consumers

With support from funding, Eva Medtec is poised for expansion and looks forward to offering an affordable, accessible solution that improves people’s daily lives. Be a part of Eva Medtec's mission by investing today!

Neuroglide™ is a Class II, over-the-counter FDA cleared medical device intended for the temporary relief of minor muscle aches and pains and for the temporary increase in circulation to the treated areas.

Code View


6300 W. Old Shakopee Road, Ste 140
Bloomington, MN 55438

Eva Medtec is a medical technology enterprise that launched commercially in 2021 with its flagship product, the Neuroglide™, and has raised $3.7M to date.


John Foster Dinusson
John Foster Dinusson
President & CEO

John was the Founder and President of OrthoCor Medical, which was acquired by Caerus Crop. He brings over 25 years of leadership in diverse areas, including venture capital, finance and operations. John’s primary experience was at Blumberg Capital, an early-stage venture capital firm that specializes in leading Seed and Series A rounds in syndication with angels, venture capital firms and strategic investors. John led Initiative Ventures where he worked with early stage Minnesota based ventures. He has worked with many successful start-up companies in obtaining financing and in their growth efforts. He currently works in an advisory capacity with several early stage companies.

Irene Anne Waldridge
Irene Anne Waldridge

Irene Waldridge, Founder & CTO. Irene Waldridge is a seasoned executive and entrepreneur with over 27 years inventing medical devices. She is the Founder of two companies, Tactile Medical and Eva Medtec. At Tactile Medical, Irene invented and developed the Flexitouch device for treating lymphedema and venous insufficiency. She has held a variety of executive positions, including CEO, Chairman of the Board and CTO. She is also the inventor of the FDA-cleared, OTC, Neuroglide™ Pain Relief and Recovery System to help patients with acute/chronic pain, and increase lymphatic circulation for the removal of harmful cellular waste from the body's soft tissues. 

David Edward Rupp
David Edward Rupp
VP of Marketing

Mr. Rupp spent 15+ years as a National Marketing Manager where he planned, created, and directed the department’s strategic plan and oversaw planning and implementation of 5 national product lines that saw company wide sales more than triple in 4 years.

Toni May Hastings
Toni May Hastings
VP of Administration

20 years of experience working with pain management clinics, and 5 years of experience with Class II medical devices, R&D and manufacturing/operations.

Mark Melin, MD

Mark Melin, MD

Medical Director

M. Mark Melin MD FACS RPVI FACCWS, is a surgeon and Medical Director of the M Health Wound Healing Institute (South Campus) and an Adjunct Associate Professor in the University of Minnesota Surgical Department. His interests and educational niches include management of lymphedema/lymphatic stasis in the wounded patient, the endothelial glycocalyx, adjunctive micronutrient and bionutrient application to wound care, diosmin Micronized Purified Flavonoid Fraction (MPFF), polygenic abnormality impact upon wound resolution, wound pH and biofilm management, and emerging technologies in wound products and wound technologies.

Dan Sipple, DO

Dan Sipple, DO

Medical Advisor

Dr. Daniel Sipple is board certified in physical medicine and rehabilitation with sub-specialty board certification in pain medicine. He trained at the Rehabilitation Institute of Chicago, now the Shirley Ryan Ability Lab, the #1 rated rehabilitation hospital in US News and World Report over 20 years running. He served on faculty at Northwestern University Medical School while working at RIC’s American Academy of Pain Medicine Center of Excellence. He subsequently practiced in Denver Colorado for two years, working along side former team physicians of the Denver Broncos and Colorado Rockies. Thereafter, at the Mayo Clinic in Eau Claire, Wisconsin via the Pain Clinic of NW Wisconsin. He served as the medical director the Health East Spine Center, and service line medical director over Neurosurgery, Behavioral Health, Pain and Spine for the health system. Dr. Sipple is the co-founder of InSitu Biologics, and co-inventor of INSB 200, sustained release non-opiate pain killer for post operative pain set to enter phase I FDA clinical trials in 2022. He is the patent holder in safe needle technology and the founder of Acies Medical. He served on the Board of Directors for the Society for Brain Mapping and Therapeutics, a NASA Spinout, and part of President Obama’s BRAIN Initiative.

Doug Goldstein, DPT

Doug Goldstein, DPT

Medical Advisor

Doug earned his Doctorate in Physical Therapy from The University of Colorado School of Medicine – Physical Therapy Program. His primary focus is in orthopedics where he is both board certified and fellowship trained. His specialization is performance enhancement and advises athletes from the NFL, NBA, USA Men’s/Women’s Soccer, MLS, MLB, UFC, USA Track and Field. He most recently founded Launchpad Fitness which utilizes AI computer vision to provide youth athletes performance training.


Eva Medtec
Mar 21, 2023
$10k - $1.23M
Common Stock
Common Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

Most Recent Fiscal Year-End

Prior Fiscal Year-End

Total Assets



Cash & Cash Equivalents



Accounts Receivable



Short-Term Debt



Long-Term Debt



Revenue & Sales



Costs of Goods Sold



Taxes Paid



Net Income



*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Investment Incentives and Bonuses*


Friends & Family Bonus

Invest within the first 48 hours and receive 20% bonus shares. 

Super Early Bird Bonus

Invest within the first week and receive 10% bonus shares.

Early Bird Bonus

Invest within the first two weeks and receive 5% bonus shares.



Invest $700 and receive 2% bonus shares. 

$1,500+ | Tier 1

Invest $1,500 and receive 4% bonus shares. 

$5,000+ | Tier 2

Invest $5,000 and receive 7% bonus shares + a Neuroglide + 30-minute call with CEO or Founder (expert in Lymphedema & MLD)  

$10,000+ | Tier 3

Invest $10,000 and receive 15% bonus shares + a Neuroglide + 30-minute call with CEO or Founder (expert in Lymphedema & MLD) 

$25,000+ | Tier 4

Invest $25,000 and receive 20% bonus shares + a Neuroglide + 30-minute call with CEO or Founder (expert in Lymphedema & MLD) 

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Eva Medtec, Inc will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Class B Non-Voting Common Stock at $3.20/share, you will receive 10 additional shares of Non-Voting Common Stock, meaning you'll own 110 shares for $320. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus in addition to the aforementioned bonus.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Salary payments made to one’s self, a friend or relative. Inter company debt or back payments.


Article Image


Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!


Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Eva Medtec.



Melinda Starbird

7 months ago

Hi there, As somebody with chronic pain from Mcas this looks interesting. Have you considered giving product discounts for investments below $5,000?



John Dinusson

Eva Medtec

7 months ago

Richard, I greatly appreciate your interest in the Neuroglide system for the back and neck. No patient is a waste of time for our company as you are who we serve. We are cleared by the FDA for pain and circulation. I have an email into our Medical Director to get his feedback on your exact situation as it relates to the Neuroglide. Please feel free to give me a call on my cell at 952-217-6366 to discuss. Best regards, John



Richard Koch

7 months ago

I'm a chronic pain patient. Without either of us parsing conditions farther than neuropathy and a trashed spine, how could this product help me? I do, for reference, have a Medtronic Syncromed II implanted pushing fentanyl into my spine. Is this the next best thing for pain patients, or just for some pain patients (which I understand). My pain doc has never mentioned this type of therapy, so don’t understand the application and to which patients and for which conditions. I'm always looking for something to make my life a little less agonizing as well as for a good investment. That said, those things that provide relief for other people do not have the same effect on me. So, let's just say, I don't want to waste your time. Thanks.



Khaleedow Bright

8 months ago

Hello, I'm Khaleedow, an expert in fundraising. I came across your campaign and see that it is not getting enough investments because it is missing out on a crucial component which is Organic promotion. I can help you promote your campaign organically and make it reach real and active investors who will be interested and willing to invest in your campaign. You can reach me out or contact me through this link below https//



John Dinusson

Eva Medtec

9 months ago

Wendy, Neuroglide is sold primarily through physicians and therapists. The Neuroglide has been approved by The FDA as a Class II OTC (over the counter) device for pain and circulation. This classification allows the Neuroglide to be sold directly to patients as well. As mentioned below the company is exploring reimbursement from Medicare, private insurance, worker's compensation and the Veteran's Administration. The company has sold over $100,000 to date via word of mouth. If you have any further question please do not hesitate to call me at 952-217-6366. Best regards, John



Wendy Bauerschmidt

9 months ago

What is the suggested price of the Neuroglide?



John Dinusson

Eva Medtec

9 months ago

Sonny, Neuroglide is sold primarily through physicians and therapists. The Neuroglide has been approved by The FDA as a Class II OTC (over the counter) device for pain and circulation. This classification allows the Neuroglide to be sold directly to patients as well. As mentioned below the company is exploring reimbursement from Medicare, private insurance, worker's compensation and the Veteran's Administration. The company has sold over $100,000to date via word of mouth. If you you have any further question please do not hesitate to call me at 952-217-6366. Best regards, John



Sonny Park

9 months ago

How much is the device? Where is it sold? TIA.



John Dinusson

Eva Medtec

9 months ago

Jerry, the Neuroglide is currently not reimbursee by Medicare. However, we are exploring coding and payment for Medicare, private insurance, workers comp and the VA. Best regards, John



Jerry Irwin

9 months ago

Will insurance reimburse for your device?




Cancel anytime before 48 hours before a rolling close or the offering end date.



We want you to succeed and get the most out of your money by offering rewards and memberships!


Your info is your info. We take pride in keeping it that way!


Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.


Get To Know Us

Our Team



Important Message

Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRASIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.
By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information

(800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.

StartEngine Marketplace

The availability of company information does not indicate that the company has endorsed, supports, or otherwise participates with StartEngine.

None of the information displayed on or downloadable from (the 'Website') represents a recommendation, offer, or solicitation of an offer to buy or sell any security. It also does not constitute an offer to provide investment advice or service. StartEngine does not (1) make any recommendations or otherwise advise on the merits or advisability of a particular investment or transaction, or (2) assist in the determination of fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.

All investment opportunities are based on indicated interest from sellers and will need to be confirmed.

Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks, and you should complete your own independent due diligence regarding the investment. This includes obtaining additional information about the company, opinions, financial projections, and legal or other investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment.

StartEngine Marketplace (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC. StartEngine Bulletin Board ("SE BB") is a bulletin board platform that advertises interest in shares of private companies that previously executed Reg CF or Reg A offerings. SE BB enables shareholders to communicate interest in potential sales of shares in private companies and investors to discover, review, and potentially invest in private companies. As a bulletin board platform, SE BB provides a venue for investors to access information about private company offerings and connect with potential sellers. SE BB is distinct and separate from StartEngine Secondary (“SE Secondary”), which is an SEC-registered Alternative Trading System (ATS) operated by SE Primary. SE Secondary facilitates the trading of securities by matching orders between buyers and sellers and facilitating executions of trades on the platform. While a security may be displayed on the bulletin board, these securities will be subject to certain restrictions which may prevent the ability to buy and sell these securities in a timely manner, if at all. Even if a security is qualified to be displayed on the bulletin board, there is no guarantee an active trading market for the securities will ever develop, or if developed, be maintained. You should assume that you may not be able to liquidate your investment for some time or be able to pledge these shares as collateral.